Journal: Molecular Cancer Therapeutics

Article Title: NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome

doi: 10.1158/1535-7163.MCT-25-0864

Figure Lengend Snippet: NOUS-209 FSMs lost, gained, and kept between paired tumors. A, Timeline plot illustrating the follow-up of patients. Filled dots indicate primary and metachronous colorectal cancer and urothelial cancer. Empty circles denote colorectal cancer for which a tumor sample is not available. Light blue lines indicate the time interval between two tumor occurrences. B, Box plot showing, for each patient, the number of NOUS-209 FSMs lost between the first and second tumor, those kept across both tumors, and those gained in the second tumor. C, Box plot showing, for each patient, the median length of NOUS-209 FSMs lost, kept, and gained. D, Bar plot showing for each patient the number of MHC-I–predicted binders (IC 50 < 500 nmol/L) for lost, kept, and gained FSMs, with annotations for B2M IHC results below for primary (P) and metachronous (M) samples. E, Box plots showing, for each patient, the number of predicted epitopes of NOUS-209 FSM lost, kept, and gained. F, Heatmap showing the FSMs lost for each patient, for whom immune editing is hypothesized. FSMs present in the patient's sample are colored if lost or kept. G, Venn diagram showing the overlap of mutations across the three tumors from patient Pt8. H–J, Line plots for patient Pt8 showing the number of NOUS-209 FSM ( H ), their median length ( I ), and the number of predicted good binders ( J ) across the lost, kept, and gained categories. CRC, colorectal cancer; UC, urothelial cancer.

Article Snippet: MHC class I peptide binding affinity predictions were conducted using the Immune Epitope Database and Analysis Resource MHC class I (MHC-I) prediction tools (RRID: SCR_006604).

Techniques: